1-(2,4-dichlorobenzyl)-5-(2,3-dichlorophenyl)-1H-1,2,3,4-tetrazole | 512182-94-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 1-(2,4-dichlorobenzyl)-5-(2,3-dichlorophenyl)-1H-1,2,3,4-tetrazole
• 英文别名: 1-(2,4-dichlorobenzyl)-5-(2,3-dichlorophenyl)-1H-tetraazole；5-(2,3-Dichlorophenyl)-1-[(2,4-dichlorophenyl)methyl]tetrazole
• CAS: 512182-94-4
• 化学式: C₁₄H₈Cl₄N₄
• 分子量: 374.056
• InChiKey: IOPAYQZQSKFZLA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.3
• 重原子数：
  22
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  43.6
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• Use of selective P2X7 receptor antagonists
  申请人：Perez-Medrano Arturo

  公开号：US20060211739A1

  公开（公告）日：2006-09-21

  The present invention relates to the use of selective P2X 7 receptor antagonists of formula I, or a pharmaceutically acceptable salt or prodrug thereof wherein D, R 1 and R 2 are as defined in claim 1 , for the treatment of neuropathic pain, chronic inflammatory pain, inflammation, neurodegeneration and for promoting neuroregeneration,

  本发明涉及使用公式I中的选择性P2X7受体拮抗剂，或其药学上可接受的盐或前药，其中D、R1和R2如权利要求书1中定义的，用于治疗神经病理性疼痛、慢性炎性疼痛、炎症、神经退行性疾病以及促进神经再生。
• REMEDIES FOR STRESS DISEASES COMPRISING MITOCHONDRIAL BENZODIAZEPINE RECEPTOR ANTAGONISTS
  申请人：ONO PHARMACEUTICAL CO., LTD.

  公开号：EP1438973A1

  公开（公告）日：2004-07-21

  A pharmaceutical composition for the prophylaxis and/or treatment of diseases induced, exacerbated or reignited by stressors comprising the compound of formula (I) wherein all symbols have the same meanings as described in the specification, etc. as an active ingredient.

  一种用于预防和/或治疗由应激源诱发、加重或复燃的疾病的药物组合物，由式 (I) 化合物组成 其中所有符号的含义与说明书中所述的相同等作为活性成分。
• Remedies for stress diseases comprising mitochondrial benzodiazepine receptor antagonists
  申请人：Seko Takuya

  公开号：US20050009812A1

  公开（公告）日：2005-01-13

  A pharmaceutical composition for the prophylaxis and/or treatment of diseases induced, exacerbated or reignited by stressors comprising the compound of formula (I) wherein all symbols have the same meanings as described in the specification, etc. as an active ingredient.
• [EN] THE USE OF SELECTIVE P2X7 RECEPTOR ANTAGONISTS<br/>[FR] UTILISATION D'ANTAGONISTES SELECTIFS DU RECEPTEUR P2X7
  申请人：ABBOTT LAB

  公开号：WO2006086229A1

  公开（公告）日：2006-08-17

  [EN] The present invention relates to the use of selective P2X₇ receptor antagonists of formula (I), or a pharmaceutically acceptable salt or prodrug thereof wherein D, R₁ and R₂ are as defined in claim 1, for the treatment of neuropathic pain, chronic inflammatory pain, inflammation, neurodegeneration and for promoting neuroregeneration.
  [FR] La présente invention concerne l'utilisation d'antagonistes sélectifs du récepteur P2X7 de formule (I), ou d'un sel ou pro-médicament pharmaceutiquement acceptable de ceux-ci, où D, R₁ et R₂ dans la formule I sont tels que définis dans la revendication 1, pour le traitement des douleurs neuropathiques, des douleurs chroniques inflammatoires, des inflammations, de la neurodégénérescence et pour favoriser la régénération neuronale.